IMWG Role of magnetic resonance imaging in the management of myeloma patients: a consensus statement

This paper, written by an expert panel on behalf of the International Myeloma Working Group, outlines the practical recommendations for the use of magnetic resonance imaging (MRI) in myeloma.

Read article

July 14, 2015

IMWG updated criteria for the diagnosis of myeloma

This paper, produced by an expert panel of the International Myeloma Working Group (IMWG), provides consensus updates on the disease definition of myeloma which now include validated biomarkers in addition to the presence of the traditional ‘CRAB’ criteria.

Read article

July 14, 2015

Orphan drug designation for novel drug CB-5083 as a treatment for myeloma

Cleave Biosciences, the US biotechnology company, has announced that its lead drug candidate CB-5083 has been granted orphan drug designation by the US Food and Drug Administration (FDA). CB-5083 is a first-in-class oral inhibitor of p97, an enzyme involved in key aspects of protein homeostasis including non-proteasomal protein degradation. Efficient removal of protein is crucial…

July 14, 2015

Details

Study shows thalidomide equally as effective as lenalidomide upfront

A study, published recently in Blood, has shown that older/less fit newly diagnosed myeloma patients treated with either melphalan, prednisolone and thalidomide (MPT-T) or melphalan, prednisolone and lenalidomide (mPR-R) had similar overall response rates, progression-free survival and overall survival. In this Phase III trial involving 306 patients with a median age of 75.7 years, median progression-free survival…

July 14, 2015

Details